{"commentary":{"count":81,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":49,"youtube":18,"podcast":13,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04586426\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RedirecTT-1","nct_id":"NCT04586426","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=redirectt-1-nct04586426. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"RedirecTT-1","arms":[{"description":"Participants will receive tec+tal in 28-day cycles following initial step-up doses. Upon sponsor notification, participants will enter the long-term extension (LTE) Phase or Drug-access Long-term Extension (DA-LTE) Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation deemed necessary by the investigator or the sponsor, or access becomes available through another source such as but not limited to commercial availability, or a patient access program.","label":"Part 1: Dose Escalation","type":"EXPERIMENTAL"},{"description":"Participants will receive treatment doses (combination of tal+tec regimen) which will be determined by the recommended Phase 2 regimen (s) (RP2R\\[s\\]) of the study treatment identified in Part 1. Upon sponsor notification, participants will enter the LTE Phase or DA-LTE Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation deemed necessary by the investigator or the sponsor, or access becomes available through another source such as but not limited to commercial availability, or a patient access program.","label":"Part 2: Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants will receive teclistamab + talquetamab combination therapy, at the RP2R selected from Part 1 and Part 2. Upon sponsor notification, participants will enter the LTE Phase or DA-LTE Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation deemed necessary by the investigator or the sponsor, or access becomes available through another source such as but not limited to commercial availability, or a patient access program.","label":"Part 3: Phase 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-10-27","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":228,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Talquetamab","type":"DRUG"},{"name":"Teclistamab","type":"DRUG"}],"last_update":"2026-01-16","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2025-03-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part 1: Number of Participants with Dose Limiting Toxicity (DLT)","timeFrame":"Approximately 5 years 10 months"},{"measure":"Part 1: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)","timeFrame":"Approximately 5 years 10 months"},{"measure":"Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability","timeFrame":"Approximately 5 years 10 months"},{"measure":"Part 2: Number of Participants with Adverse Events and SAEs by Severity","timeFrame":"Approximately 5 years 10 months"},{"measure":"Part 3: Overall Response Rate (ORR)","timeFrame":"Approximately 5 years 10 months"}],"references":[{"citation":"Kumar S, Mateos MV, Ye JC, Atrash S, Magen H, Quach H, Chu MP, Trudel S, Richter J, Rodriguez-Otero P, Chuah H, Gatt M, Medvedova E, Raza S, Yoon DH, Ishida T, Matous JV, Rosinol L, Onodera K, Scott E, Heuck C, Zhang J, Henninger T, O'Rourke L, Thakkar P, Festa M, Huang L, Zhou J, Takamoto M, Pei L, Lu J, Au N, Krevvata M, Usmani SZ, Cohen YC; RedirecTT-1 Investigators Study Group. Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab. N Engl J Med. 2026 Jan 1;394(1):51-61. doi: 10.1056/NEJMoa2514752. Epub 2025 Dec 7.","pmid":"41358582","type":"DERIVED"},{"citation":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, Ocio EM, Yoon SS, Chu MP, Rodriguez-Otero P, Avivi I, Quijano Carde NA, Kumar A, Krevvata M, Peterson MR, Di Scala L, Scott E, Hilder B, Vanak J, Banerjee A, Oriol A, Morillo D, Mateos MV; RedirecTT-1 Investigators and Study Group. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2025 Jan 9;392(2):138-149. doi: 10.1056/NEJMoa2406536.","pmid":"39778168","type":"DERIVED"},{"citation":"St Martin Y, Franz JK, Agha ME, Lazarus HM. Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need. Blood Rev. 2023 Jul;60:101095. doi: 10.1016/j.blre.2023.101095. Epub 2023 Apr 29.","pmid":"37173224","type":"DERIVED"}],"start_date":{"date":"2020-12-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT04586426"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/redirectt-1-nct04586426"}